Gufic BioSciences Ltd

₹421.3▼ -0.38%28 Sept

📊 Stock Analysis

Market Data

Market Cap₹4,224.9 Cr.

52W High₹466.05

Current Price₹421.3

52W Low₹267.5

Down from 52W High9.6 %

Face Value₹1

Performance

ROCE12.95 %

ROE11.05 %

EPS (TTM)₹2.22

EPS Prev Qtr₹2.18

EPS Last Year₹1.68

EBITDA Qtr₹38.9 Cr.

Book Value₹66

Financial Health

Debt/Equity0.58

Debt/Profit5.24

Total Assets₹1,342.374 Cr.

Dividend Yield0.02 %

Promoter Holding72.5 %

Earning Power9.97 %

Valuation

Stock P/E57.55

Industry P/E33.81

Price to Book6.35

Price to Sales4.31

Graham Number₹104.53

Key Metrics

__derived

Face Value

₹1

About Gufic BioSciences Ltd

Healthcare · Pharmaceuticals

Gufic BioSciences Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹4,224.9 Cr.

Price Chart

Peer Comparison

Name	CMP	P/E	Market Cap	Div Yield	NP Qtr	Qtr Profit Var%	Sales Qtr	Qtr Sales Var%	ROCE%	Debt/Eq
Sun Pharmaceutical Industries Ltd	-	36.51	₹4,41,477.63 Cr	0.87%	₹12,172.7 Cr	-	₹59,910.52 Cr	-	18.72%	0.05
Divis Laboratories Ltd	-	86.48	₹2,53,031.38 Cr	0.31%	₹2,925 Cr	-	₹11,230 Cr	-	23.04%	0
Torrent Pharmaceuticals Ltd	-	77.67	₹1,85,216.32 Cr	0.78%	₹2,156 Cr	-	₹15,723 Cr	-	15.1%	1.76
Zydus Lifesciences Ltd	-	27.01	₹1,20,897.46 Cr	0.08%	₹4,492.2 Cr	-	₹28,591.7 Cr	-	16.76%	0.43
Cipla Ltd	-	33.28	₹1,12,201.64 Cr	0.94%	₹3,364.84 Cr	-	₹28,324.4 Cr	-	13.24%	0.01
Laurus Labs Ltd	-	99.31	₹1,08,698.22 Cr	0.06%	₹1,090.76 Cr	-	₹7,269.64 Cr	-	20.79%	0.45
Dr Reddys Laboratories Ltd	-	31.6	₹1,02,039.12 Cr	0.65%	₹3,183.3 Cr	-	₹33,227.9 Cr	-	10.05%	0.17
Mankind Pharma Ltd	-	49.29	₹1,00,752.43 Cr	0.04%	₹2,067.57 Cr	-	₹14,737.88 Cr	-	13.95%	0.38
Aurobindo Pharma Ltd	-	26.56	₹97,814.24 Cr	0.24%	₹3,710.8 Cr	-	₹34,935.29 Cr	-	12.75%	0.2
Lupin Ltd	-	16.64	₹94,274.49 Cr	0.87%	₹5,550.99 Cr	-	₹29,966.58 Cr	-	27.95%	0.26
Glenmark Pharmaceuticals Ltd	-	36.67	₹65,922.11 Cr	0.11%	₹1,797.81 Cr	-	₹17,736.56 Cr	-	24.78%	0.25
Alkem Laboratories Ltd	-	28.65	₹61,804.34 Cr	1.03%	₹2,206.3 Cr	-	₹15,081.28 Cr	-	19.75%	0.12
Biocon Ltd	-	110.29	₹61,113.53 Cr	0.13%	₹416.4 Cr	-	₹17,321.1 Cr	-	2.87%	0.43
Abbott India Ltd	-	35.22	₹56,860.69 Cr	1.78%	₹1,614.68 Cr	-	₹7,004.38 Cr	-	45.73%	0
Glaxosmithkline Pharmaceuticals Ltd	-	46.73	₹49,091.33 Cr	1.97%	₹1,068.15 Cr	-	₹3,954.94 Cr	-	64.07%	0
Ipca Laboratories Ltd	-	36.13	₹48,712.48 Cr	0.31%	₹1,379.76 Cr	-	₹10,125.58 Cr	-	21.48%	0.09
Anthem Biosciences Ltd	-	83.03	₹47,949.68 Cr	0.23%	₹575.95 Cr	-	₹2,002.34 Cr	-	25.5%	0.02
Gland Pharma Ltd	-	42.26	₹47,764.08 Cr	0.69%	₹1,128.8 Cr	-	₹6,725.3 Cr	-	15.21%	0.02
Ajanta Pharma Ltd	-	38.87	₹44,109.77 Cr	0.79%	₹1,134.88 Cr	-	₹5,776.17 Cr	-	31.81%	0.05
J B Chemicals & Pharmaceuticals Ltd	-	53.3	₹38,730.77 Cr	0.39%	₹709.46 Cr	-	₹4,147.79 Cr	-	23.03%	0

Quarterly Results

📊 Jun 2026: Revenue grew 16.6% YoY, Profit grew 70.7% YoY

	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	223.73	237.05	231.41	251.82	260.82
↳ QoQ Growth	-	+6.0%	-2.4%	+8.8%	+3.6%
Expenses	198.14	206.98	206.12	212.26	221.92
Operating Profit	25.59	30.07	25.29	39.56	38.9
OPM %	11.44%	12.69%	10.93%	15.71%	14.91%
Other Income	0.92	2.12	0.79	-1.17	0.46
Interest	9.24	9.58	8.36	9.44	9.32
Depreciation	7.72	7.77	7.69	7.65	7.71
EBITDA	33.31	37.84	32.98	47.21	46.61
EBITDA Margin %	14.89%	15.96%	14.25%	18.75%	17.87%
Profit Before Tax	17.28	22.6	17.72	28.95	30.04
Tax %	24.36%	25.58%	29.91%	24.35%	25.73%
Net Profit	13.07	16.82	12.42	21.9	22.31
↳ QoQ Growth	-	+28.7%	-26.2%	+76.3%	+1.9%
EPS	1.3	1.68	1.24	2.18	2.22

Profit & Loss

	Mar 2026	TTM
Sales	944.01	981.1
Expenses	823.5	847.28
Operating Profit	120.51	133.82
OPM %	12.77%	13.64%
Other Income	2.66	2.2
Interest	36.62	36.7
Depreciation	30.83	30.82
Profit Before Tax	86.55	99.31
Tax %	25.81%	26.04%
Net Profit	64.21	73.45
EPS	6.4	7.32

Compounded Sales Growth

10Y

TTM

Compounded Profit Growth

10Y

TTM

Stock Price CAGR

10Y

19.38%

Return on Equity

10Y

Last Year

11.05%

Balance Sheet

	Mar 2025	Mar 2026
Equity Capital	10.03	10.0283
Reserves	591.05	654.9203
Borrowings	336.19	385.16
Other Liabilities	232.09	292.27
Total Liabilities	1169.36	1342.374
Fixed Assets	499.65	491.0162
CWIP	21.82	22.1446
Investments	1.78	1.78
Other Assets	646.11	827.43
Total Assets	1169.36	1342.374

Cash Flows

	Mar 2025	Mar 2026
Cash from Operating Activity	122.5679	45.1394
Cash from Investing Activity	-70.7773	-30.9642
Cash from Financing Activity	-37.2041	32.2873
Net Cash Flow	14.5865	46.4625

Ratios

	Mar 2026
Debtor Days	-
Inventory Days	-
Days Payable	-
Cash Conversion Cycle	-
Working Capital Days	370.11
ROCE %	12.59%

Shareholding Pattern

	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters %	72.5%	72.5%	72.5%	72.5%
FIIs %	0.34%	0.44%	0.42%	0.46%
DIIs %	3.66%	3.74%	3.83%	3.67%
Public %	14.45%	14.13%	13.93%	14%
No. of Shareholders	31,420	30,362	29,223	29,753